Curis | CRIS - Ebit


Curis reported $-12.37M in EBIT for its fiscal quarter ending in September of 2023.





Ebit Change Date
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bayer EUR 1.11B 1.51B Dec/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
CSL USD 2.64B 116M Dec/2025
Curis USD -12.37M 230K Sep/2023
Eli Lilly USD 8.99B 1.57B Dec/2025
Exelixis USD 235.91M 20.45M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Incyte USD 383.88M 47.44M Dec/2025
Merck USD 6.24B 1.32B Dec/2025
Novartis USD 4.06B 530M Dec/2025
Pfizer USD 4.65B 71M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Takeda JPY 257.49B 568.56B Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025
Verastem USD -37.03M 6M Sep/2024
Xoma USD -10.08M 4.4M Jun/2024